logo
New dog-sized dinosaur species discovered

New dog-sized dinosaur species discovered

CNN25-06-2025
Scientists have discovered a new species of dinosaur — one that was dog-sized and roamed what is now the United States around 150 million years ago alongside familiar dinosaurs like stegosaurus and diplodocus.
The Enigmacursor mollyborthwickae, as researchers named it, was about the same size as a Labrador retriever, with a tail that made up about half of its length, according to a study published in the Royal Society Open Science on Wednesday.
Although many of its bones were unearthed from the Morrison Formation in Colorado in 2021-2022, its skull and parts of its vertebral column were missing, leaving scientists unsure of its precise length.
'These very small plant-eating dinosaurs are pretty rare (to find),' Professor Paul Barrett, a researcher at London's Natural History Museum who co-led the study, told CNN.
'Actually finding a substantially completed skeleton rather than a few bits and pieces of bones is not common and as a result they're fairly poorly known.'
The skeleton will be displayed at the Natural History Museum from June 26.
This dinosaur was quite 'lightly built' and weighed around the same as a collie, said Barrett. It was a herbivore and would have walked on its long hind legs, which 'suggests it was quite a speedy runner' allowing it to make a 'quick getaway' from predators, Barrett added.
He and his colleague, Susannah Maidment, began investigating this specimen after a London art gallery, which was displaying the dinosaur, got in contact with them.
They were eventually able to work with the gallery to find a donor who could help bring the skeleton to the museum. The species name honors that donor, Molly Borthwick, while the genus name is Latin for 'mysterious runner.'
By carefully examining the bones, Maidment and Barrett concluded that this specimen had unique characteristics unlike any other previously known species. In particular, its thigh bone was particularly distinctive, with different sorts of muscle attachments than other dinosaurs, Barrett said.
It is most closely related to Yandusaurus hongheenis, a three-meter- (9.8-foot) long dinosaur that has been found in China. This suggests the species was widely distributed, Barrett said, hypothesizing that other fossils of it simply haven't been found yet.
Scientists believe this specimen was not yet fully grown as some of its vertebrae had not yet fused but, because of the way the fossil was prepared before it came to the Natural History Museum, they can't be certain. It is also not clear how the dinosaur died because there aren't any obvious signs of illness or injury in its bones.
New species of dinosaurs are unearthed or identified relatively frequently, about once a week, said Barrett. But finding small dinosaurs like this is much rarer, partly because they're overlooked by fossil hunters searching for bigger, more impressive dinosaurs and partly because smaller skeletons are more likely to be ripped apart by predators and scavengers.
Finding these smaller dinosaurs which are often left in the ground 'gives us a more complete idea of what those ecosystems were like,' Barrett said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time17 minutes ago

  • Yahoo

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at with an archived replay available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the US. For additional information about Sagimet, please visit Investor Contact:Joyce Allaire LifeSci Advisors JAllaire@ Media Contact:Michael FitzhughLifeSci Advisors mfitzhugh@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center
Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Yahoo

timean hour ago

  • Yahoo

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Future Surgical Center to Be Powered by OMNIMED SmartOR™ Technology, Anchored on a World-Class University Campus and Driven by Axis Research IRVINE, Calif., August 05, 2025--(BUSINESS WIRE)--Axis Research & Technologies, a national leader in bioskills training and medical research environments, proudly marks its 10-year anniversary with a decade of expansion, innovation, and trusted partnerships across the healthcare ecosystem. As it celebrates this milestone, the company unveils its bold next step: a strategic initiative to build the nation's first AI-powered smart surgical center in collaboration with a world-class university. This next-generation facility will unite cadaveric training, surgical simulation, real-time telemetry, and AI-driven insights to support clinical education, medical device innovation, and procedural performance at scale. "We've spent the last 10 years building a trusted network of innovation and excellence," said Nick Moran, Chief Executive Officer of Axis. "As we look to the next decade, our vision is to evolve from best-in-class bioskills labs to the development of intelligent, integrated surgical ecosystems that accelerate discovery and improve outcomes." A National Network Built for Innovation Founded in 2015, Axis operates a network of advanced bioskills labs in Irvine, CA; Columbia (Baltimore), MD; Nashville, TN; and Houston, TX. Each facility is designed to accommodate complex, hands-on surgical training, cadaveric research, device development, and live broadcast education—all supported by Axis's experienced logistics, tissue sourcing, and technical teams. The company's Houston lab, launched in 2025, is strategically located near the Texas Medical Center and continues the Axis tradition of pairing location intelligence with industry demand to better serve surgeons, educators, and medtech leaders. "We've scaled carefully and intentionally to meet the needs of our partners," said Moran. "And now, we're focused on shaping what comes next—where performance, insight, and education converge." OMNIMED and SmartOR™: Powering Data-Driven Surgical Environments Several years ago, Axis became an early adopter and integration partner of OMNIMED™, a medical technology company that had been developing SmartOR™—a first-of-its-kind AI surgical telemetry platform. SmartOR™ captures real-time data across classroom, simulation, and operating room environments, giving educators, researchers, and developers unprecedented insight into tools, workflows, and performance outcomes. OMNIMED's platform is now fully embedded within Axis facilities, enabling predictive modeling, skill gap analysis, protocol validation, and real-time diagnostics. "We're no longer limited to what we can see," said Moran. "Now, we can measure, model, and improve with clarity, speed, and scale." A Strategic Vision for the Future of Surgery As part of its next phase of growth, Axis has announced its intent to align with a premier academic institution to co-develop a 36,000 sq. ft. smart surgical center—designed as a national hub for surgical innovation, clinical research, and medical education. This initiative is a logical and mission-aligned evolution of Axis's capabilities, combining physical infrastructure with proven technology and real-world surgical telemetry. By collaborating with the right university partner, Axis aims to accelerate translational research, bridge academic and industry priorities, and train future generations of surgeons within a connected, data-rich ecosystem. "Axis is committed to working with the ideal institutional partner—one that shares our belief that surgical excellence requires measurable feedback, collaborative design, and intelligent infrastructure," said Jill Goodwin, Chief Operating Officer of Axis. The company will continue developing the center in alignment with its founding principles—creating flexible, scalable environments that connect education, experimentation, and evidence—all in one location. Looking Ahead As Axis enters its second decade, it remains committed to being the platform for surgical progress—delivering training spaces, simulation technologies, and insights that help industry leaders bring better procedures, devices, and outcomes to life. About Axis Research & Technologies Axis operates a national network of advanced bioskills labs that support surgical training, cadaver-based research, and healthcare innovation. With hands-on environments, concierge-level support, and cutting-edge broadcasting and analytics capabilities, Axis serves as a trusted partner to medical device companies, health systems, and academic institutions. Learn more at About OMNIMED OMNIMED is the creator of SmartOR™, an AI-powered surgical telemetry platform that links classroom, simulation, and operating room data into a measurable, intelligent system. Used by educators, clinicians, and developers, SmartOR™ delivers actionable insights to improve training, device testing, and surgical performance. Learn more at View source version on Contacts Media Contact: Kim ShermanOpen Door Consultingkim@

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Yahoo

timean hour ago

  • Yahoo

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ('Jeune'), a wholly owned subsidiary of Krystal Biotech, Inc. ('Krystal') (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS). GAIS assesses the overall aesthetic change in appearance as a result of a treatment. Subjects also reported increased satisfaction with the appearance of wrinkles, as measured by the Subject Satisfaction Questionnaire (SSQ). The SSQ is a tool to gather subject-reported outcomes providing valuable insights on the impact of treatment beyond clinical observations. Topline Efficacy Results A total of 19 subjects were enrolled, 12 were randomized to KB304 and seven to placebo. One subject dropped out before completing KB304 treatments. The remaining 18 subjects were assessed for aesthetic improvement out to three months following KB304 injections in the décolleté. The study investigator and subjects reported a clinically meaningful improvement in wrinkles one, two, and three months after treatment, as assessed by GAIS among KB304-treated subjects. Investigator Reported: At Least One-Point Improvement for Subjects Receiving: Subject Reported: At Least One-Point Improvement for Subjects Receiving: KB304 Placebo KB304 Placebo At Three Months 100% 28.6% 72.7% 14.3% At Two Months 100% 28.6% 90.9% 14.3% At One Month 100% 14.3% 72.7% 14.3% As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of subjects receiving placebo. Improvements in subjects receiving KB304 were also seen across multiple additional skin attributes, as assessed by GAIS, including elasticity, crepiness, hydration, and radiance, for which the investigator reported that 100% of subjects demonstrated an improvement of at least 1 point in each of these attributes at one, two, and three months following treatment. 'We are very excited to share today's data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways…being the first product candidate to directly address elastin and by doing so in the décolleté where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance,' said Marc Forth, Chief Executive Officer of Jeune. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported. 'We are extremely excited by the promising data from the Pearl-2 study,' said Suma Krishnan, President of Research & Development at Krystal Biotech. 'We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body's own skin cells. On the basis of the strong results and broad improvements across multiple skin aesthetic attributes, we will be progressing KB304 into Phase 2 development for the treatment of wrinkles in the décolleté, a priority aesthetic site for which no FDA-approved injectables exist. We plan to prioritize the development of KB304 and will be meeting with the FDA in the coming months to enable initiation of the Phase 2 study.' Jeune has recently completed development and validation of a décolleté-specific photonumeric scale ('JDWS'). Jeune intends to submit the JDWS to the FDA and align on the Phase 2 study protocol in the second half of 2025 with the goal of initiating the Phase 2 study in the first half of 2026. Conference Call and Webcast Jeune and Krystal will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, Jeune's pipeline product candidates, and the strategic vision for Jeune. Investors and the general public can access the live webcast at: For those unable to listen to the live webcast, a replay will be available on the Investor's section of the Krystal website at About KB304 KB304 is an investigational aesthetic therapy employing Krystal's novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin's extracellular matrix. KB304 is formulated as a solution for direct intradermal injection to aesthetic priority areas. About the PEARL-2 Study PEARL-2 is a Phase 1 Study of KB304, a replication-defective, non-integrating vector expressing human type III collagen (COL3) and elastin for the treatment of moderate to severe wrinkles of the décolleté. Details of the Phase 1 study can be found at under NCT identifier NCT06724900. About Jeune Aesthetics, Inc. Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit and follow @KrystalBiotech on LinkedIn and X (formerly Twitter). Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about the clinical utility of KB304; KB304's ability to deliver collagen and elastin to restore the skin naturally to a more youthful appearance and potentially revolutionize the treatment of wrinkles and skin quality; KB304's potential to address a massive gap in the market; Krystal's and Jeune's plans to prioritize the development of KB304 and progress KB304 into a Phase 2 study for the treatment of wrinkles of the décolleté, including timing of meeting with the FDA and the goal of initiating the Phase 2 study in the first half of 2026; and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'likely,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies; uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of KB304, and such other important factors as are set forth under the caption 'Risk Factors' in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's and Jeune's views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's and Jeune's views as of any date subsequent to the date of this press release. CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@ Nishant Saxena Jeune Aesthetics nsaxena@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store